RAPT Therapeutics Strengthens Scientific Leadership with Major CSO Stock Package

Rhea-AI Filing Summary

RAPT Therapeutics Chief Scientific Officer Dirk G. Brockstedt received a new stock option grant on June 20, 2025. The derivative securities transaction details include:

• Grant of 100,000 stock options to purchase common stock
• Exercise price set at $7.43 per share
• Options expire on June 19, 2035
• Vesting schedule: 1/48th of shares vest monthly from June 20, 2025

This Form 4 filing represents a standard equity compensation grant to a senior executive, likely as part of the company's long-term incentive program. The 10-year option term and 4-year monthly vesting schedule are typical for executive compensation in the biotech industry, designed to promote long-term retention and align management interests with shareholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brockstedt Dirk G.

(Last) (First) (Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$7.43	06/20/2025		A		100,000		(1)	06/19/2035	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. 1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of June 20, 2025.

	/s/ Rodney Young, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did RAPT's Chief Scientific Officer receive on June 20, 2025?

RAPT Therapeutics' Chief Scientific Officer Dirk G. Brockstedt received 100,000 employee stock options with an exercise price of $7.43 per share on June 20, 2025.

What is the vesting schedule for RAPT CSO's June 2025 stock options?

The stock options vest monthly over 4 years, with 1/48th of the shares vesting each month following the vesting commencement date of June 20, 2025.

When do RAPT CSO Dirk Brockstedt's stock options expire?

The employee stock options granted to Dirk Brockstedt expire on June 19, 2035, ten years after the grant date.

What is the exercise price of RAPT Therapeutics' stock options granted to the CSO in June 2025?

The exercise price of the stock options granted to RAPT's Chief Scientific Officer is $7.43 per share.

Who filed the Form 4 for RAPT Therapeutics' CSO stock option grant?

The Form 4 was signed by Rodney Young as Attorney-in-Fact for Dirk G. Brockstedt on June 24, 2025.